Literature DB >> 19501251

Pharmacotherapy for the obese patient.

Lori M Dickerson1, Peter J Carek.   

Abstract

The long-term safety of many antiobesity pharmacologic regimens has not been adequately evaluated. If recommended and prescribed, pharmacologic agents should be an adjunct to a structured diet and exercise regimen. Unfortunately, weight gain after discontinuation of antiobesity agents is common. In addition, the effect of weight loss obtained through the use of pharmacotherapeutic agents on overall morbidity and mortality has not been established.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19501251     DOI: 10.1016/j.pop.2009.01.004

Source DB:  PubMed          Journal:  Prim Care        ISSN: 0095-4543            Impact factor:   2.907


  3 in total

1.  Pharmacological inhibition of diacylglycerol acyltransferase 1 reduces body weight gain, hyperlipidemia, and hepatic steatosis in db/db mice.

Authors:  Xiao-dong Zhang; Jian-wei Yan; Gui-rui Yan; Xiao-yun Sun; Jun Ji; Yi-ming Li; You-hong Hu; He-yao Wang
Journal:  Acta Pharmacol Sin       Date:  2010-11       Impact factor: 6.150

2.  The tobacco industry's past role in weight control related to smoking.

Authors:  Semira Gonseth; Isabelle Jacot-Sadowski; Pascal A Diethelm; Vincent Barras; Jacques Cornuz
Journal:  Eur J Public Health       Date:  2011-04-07       Impact factor: 3.367

3.  Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity.

Authors:  Jin Hee Shin; Kishore M Gadde
Journal:  Diabetes Metab Syndr Obes       Date:  2013-04-08       Impact factor: 3.168

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.